4.24

1.92% 0.08

After Hours: 4.24

Foghorn Therapeutics Inc (FHTX)

Overview News Price History Option Chain Financials Why FHTX Down? Discussions Forecast

Foghorn Therapeutics Inc stock is traded at $4.24, with a volume of 108.88K. It is up +1.92% in the last 24 hours and up +23.98% over the past month. Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Previous Close:

$4.16

Open:

$4.21

24h Volume:

108.88K

Relative Volume:

0.83

Market Cap:

$242.47M

Revenue:

$34.16M

Net Income/Loss:

$-98.43M

P/E Ratio:

-1.812

EPS:

-2.34

Net Cash Flow:

$-119.33M

1W Performance:

-2.75%

1M Performance:

+23.98%

6M Performance:

-48.92%

1Y Performance:

-30.61%

1-Day Range:

$4.08

$4.34

1-Week Range:

$4.00

$4.51

52-Week Range:

$2.9448

$10.25

Foghorn Therapeutics Inc Stock (FHTX) Company Profile

Name

Foghorn Therapeutics Inc

Sector

Healthcare (1152)

Industry

Biotechnology (677)

Phone

617-586-3100

Address

500 TECHNOLOGY SQUARE, CAMBRIDGE

Employee

112

Twitter

Next Earnings Date

2025-03-07

Latest SEC Filings

FHTX's Discussions on Twitter

Compare FHTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FHTX Foghorn Therapeutics Inc	4.24	242.47M	34.16M	-98.43M	-119.33M	-2.34
VRTX Vertex Pharmaceuticals Inc	501.15	126.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	605.61	65.06B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	649.67	37.54B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	259.39	32.56B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	255.77	26.40B	3.81B	-644.79M	-669.77M	-6.24

Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-23-25	Initiated	Citizens JMP	Mkt Outperform
Jan-30-25	Initiated	B. Riley Securities	Buy
Sep-03-24	Initiated	Jefferies	Buy
Aug-19-24	Initiated	Evercore ISI	Outperform
Mar-28-23	Initiated	BofA Securities	Buy
Jan-05-23	Initiated	BMO Capital Markets	Outperform
Nov-22-21	Initiated	H.C. Wainwright	Buy
Nov-17-20	Initiated	Cowen	Outperform
Nov-17-20	Initiated	Goldman	Buy
Nov-17-20	Initiated	Morgan Stanley	Overweight
Nov-17-20	Initiated	Wedbush	Outperform

View All

Foghorn Therapeutics Inc Stock (FHTX) Latest News

03:22 AM

JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics (NASDAQ:FHTX) - Defense World

03:22 AM

May 01, 2025

Foghorn Therapeutics expands board with biotech veterans By Investing.com - Investing.com India

May 01, 2025

Foghorn Therapeutics expands board with biotech veterans - Investing.com

May 01, 2025

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire

May 01, 2025

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire Inc.

May 01, 2025

Apr 29, 2025

Foghorn Therapeutics Presents New Preclinical Data on Selective - GuruFocus

Apr 29, 2025

Geode Capital Management LLC Boosts Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Apr 29, 2025

Apr 28, 2025

Breakthrough Cancer Drug FHD-909 Shows Synergy with Leading Treatments in Lung Cancer Studies - Stock Titan

Apr 28, 2025

Apr 26, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Research Coverage Started at JMP Securities - Defense World

Apr 26, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Earns Mkt Outperform Rating from Analysts at Citizens Jmp - Defense World

Apr 26, 2025

Apr 23, 2025

This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Apr 23, 2025

JMP Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Market Outperform Recommendation - Nasdaq

Apr 23, 2025

Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Targ - GuruFocus

Apr 23, 2025

Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Target | FHTX Stock News - GuruFocus

Apr 23, 2025

Apr 18, 2025

Brokerages Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Price Target at $13.17 - Defense World

Apr 18, 2025

Apr 15, 2025

Foghorn Therapeutics to Host Virtual Investor Event to Review Pi - GuruFocus

Apr 15, 2025

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting | FHTX Stock News - GuruFocus

Apr 15, 2025

Foghorn Therapeutics to Host Virtual Investor Event to - GlobeNewswire

Apr 15, 2025

Major Pipeline Breakthrough: Foghorn's First-in-Class Cancer Drug Shows Promise in NSCLC Treatment - Stock Titan

Apr 15, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Bought by Wellington Management Group LLP - Defense World

Apr 15, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Trading 4.1% Higher – Time to Buy? - Defense World

Apr 15, 2025

Apr 09, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely - simplywall.st

Apr 09, 2025

Apr 07, 2025

(FHTX) Technical Data - news.stocktradersdaily.com

Apr 07, 2025

Apr 02, 2025